Editorial: Androgen-Dependent Diseases And Their Treatment

December 2024 in “ Frontiers in Endocrinology ”

Marisa Cabeza

androgen-dependent diseases metastatic castration-resistant prostate cancer benign prostatic hyperplasia polycystic ovary syndrome CRPC BPH PCOS olaparib abiraterone hyperandrogenism androstenedione

Studysummary This research reviewed existing literature to explore treatment options for androgen-dependent diseases, reporting that among prostate cancer therapies analyzed, the drug olaparib as monotherapy resulted in longer survival compared to the combination of apalutamide and abiraterone, though combined treatment efficacy differences were not statistically significant.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer ·

View this study on frontiersin.org →

Discuss this study in the Community →

Related Community Posts Join

6 / 1000+ results

community Female, 30, PCOS diagnosis, MPB Norwood 2. Endo refuses to give anything other than Spironolactone. Feel like I’m at my wit’s end here.

55 upvotes 2 years ago

A 30-year-old female with PCOS and male pattern baldness is frustrated with her endocrinologist's recommendation of only Spironolactone and minoxidil, feeling that dutasteride, finasteride, and progesterone would be more effective. Other users suggest various online sources for treatments, warn against self-medicating due to potential risks, and recommend seeking a specialized endocrinologist or considering additional treatments like Inositol, Berberine, and dermaneedling.

community Female androgenetic alopecia (w/ PCOS) starting treatment

4 upvotes 1 year ago

A female with PCOS and androgenetic alopecia is starting treatment with oral Minoxidil, topical Minoxidil 5% with finasteride, and plans to add mesotherapy. She previously tried anti-androgenic contraceptive pills but couldn't tolerate them and is using Myo Inositol for weight management.

community Pattern hair loss before the age of 35 is associated with higher chances of prostate cancer, cardiovascular diseases, and metabolic syndrome later in life

1075 upvotes 3 months ago

Pattern hair loss before age 35 may be linked to higher risks of prostate cancer, cardiovascular diseases, and metabolic syndrome later in life. Finasteride is discussed as a treatment that may lower PSA levels and potentially prevent prostate issues.

community Does anyone have any experience with Estradiol, Cyproterone Acetate, Spironolactone, Bicalutamide ?

4 upvotes 6 years ago

Some users have experienced good hair regrowth with estradiol, cyproterone acetate, spironolactone, and bicalutamide, but these treatments may cause feminization and other side effects. It's advised to consult a doctor before using these treatments, as they can lower testosterone and have significant risks.

community Has anyone had success treating androgenic hair loss topically?

4 upvotes 3 months ago

A woman with androgenic hair loss, likely due to PCOS, is seeking topical treatments as oral medications are not an option. Suggested treatments include topical finasteride, spironolactone, and clascoterone, with spironolactone and clascoterone being safer options due to lower systemic absorption risk.

community Why is everyone still arguing about PP405 when clascoterone is already heading toward regulatory submission?

46 upvotes 1 month ago

Clascoterone is nearing regulatory submission as a potential new treatment for androgenetic alopecia, with positive Phase III results, while discussions continue about other treatments like PP405, minoxidil, and finasteride. Some users express excitement for clascoterone and Breezula, despite concerns about the effectiveness and practicality of topical treatments.

Similar Research

5 / 1000+ results

research Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases

11 citations , February 2016 in “Current Medicinal Chemistry”

This review discusses various targets for treating prostate cancer and benign prostatic hyperplasia and reports on recent studies of new compounds and 5α-reductase inhibitors, but provides no new experimental results.

research Endocrinology of the Aging Prostate: Current Concepts

21 citations , February 2021 in “Frontiers in Endocrinology”

This review explores the potential impact of hormonal changes during aging on benign prostate hyperplasia-related urinary symptoms and metabolic syndrome, highlighting the hypothesis of a male PCOS-equivalent but reports no new clinical results.

research Editorial Comments

November 2007 in “The Journal of Urology”

This editorial comments on long-term treatment options for benign prostatic hyperplasia but reports no new research findings.

research Antiandrogens: Clinical applications

39 citations , November 1990 in “The Journal of Steroid Biochemistry and Molecular Biology”

This abstract reviews the use and effects of various antiandrogens, finding clinical benefits in treating hyperandrogenism in women and improvements in urinary symptoms or cancer management in men, but it reports no new clinical results.

research Postmenopausal hyperandrogenism

15 citations , May 2021 in “Climacteric”

This review discusses the characteristics, diagnostic challenges, and management options for postmenopausal hyperandrogenism but reports no new clinical results; it highlights the importance of distinguishing potential androgen-producing tumors or hyperandrogenic disorders.